Reference
Etges T, et al. An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex (THC: CBD, nabiximols) oromucosal spray. Therapeutics and Clinical Risk Management 12: 1667-1675, 11 Nov 2016. Available from: URL: http://doi.org/10.2147/TCRM.S115014 - United Kingdom
Rights and permissions
About this article
Cite this article
Nabiximols. Reactions Weekly 1635, 228 (2017). https://doi.org/10.1007/s40278-017-25477-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-25477-z